President & Chief Executive Officer
Richard Russo is President & CEO of the Company and also a board member. Richard is a veteran of the Medtech space and has been successful in both corporate and start-up firms. Prior to joining to joining Endomedix, Richard was the CEO of a French start-up, OST Développement SA (subsidiary of Osteotech, a NASDAQ firm). Starting with a base of virtually no customers, OST quickly built up a $20+M business by pioneering a new concept product in Europe, Latin America & Asia. The company was subsequently acquired by Medtronic. Richard was also a seed investor and manager (clinical research & regulatory affairs) in a Medtech start-up, Meditron which successfully developed and commercialize a Class III device and was acquired by Cross Medical. Richard has also worked at major public firms such as American Hospital Supply (now Baxter International), CR Bard, Electro-Biology (now Biomet) and American Sterilizer in a marketing, strategic planning and business development, sales, clinical research and regulatory affairs leadership roles. He has demonstrated strength in new product development and in clinical research & regulatory affairs by successfully commercializing new products and obtaining regulatory approvals including two PMA’s and CE mark for Class III devices. He was chair of the Governmental Affairs Committee for the human tissue industry group during FDA’s development of regulations for this sector. Since joining Endomedix in 2009, Richard has revised the Company’s business model and technical direction and re-established its laboratory and product development team, leading to the creation of a novel platform technology with 8 issued patents. He has also become the Company’s lead investor. Richard earned a BA cum laude at Boston College and a MBA at Columbia Business School.